Search hospitals > Michigan > Adrian

Hickman Cancer Center at Bixby Medical Center

Claim this profile
Adrian, Michigan 49221
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
200 reported clinical trials
1 medical researcher
Photo of Hickman Cancer Center at Bixby Medical Center in AdrianPhoto of Hickman Cancer Center at Bixby Medical Center in AdrianPhoto of Hickman Cancer Center at Bixby Medical Center in Adrian

Summary

Hickman Cancer Center at Bixby Medical Center is a medical facility located in Adrian, Michigan. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Hickman Cancer Center at Bixby Medical Center is involved with conducting 200 clinical trials across 329 conditions. There are 1 research doctors associated with this hospital, such as REX MOWAT, MD.

Area of expertise

1Breast Cancer
Global Leader
Hickman Cancer Center at Bixby Medical Center has run 69 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive
2Cancer
Global Leader
Hickman Cancer Center at Bixby Medical Center has run 62 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Hickman Cancer Center at Bixby Medical Center

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Cancer
Cutaneous Melanoma
Melanoma
Bladder Cancer
Pancreatic Carcinoma
Multiple Myeloma
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Sacituzumab Govitecan

for Brain Metastases from Breast Cancer

This study is evaluating whether a combination of a chemotherapy drug and a monoclonal antibody may help treat breast cancer that has spread to the brain.
Recruiting1 award Phase 212 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hickman Cancer Center at Bixby Medical Center?
Hickman Cancer Center at Bixby Medical Center is a medical facility located in Adrian, Michigan. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Hickman Cancer Center at Bixby Medical Center is involved with conducting 200 clinical trials across 329 conditions. There are 1 research doctors associated with this hospital, such as REX MOWAT, MD.